SCHEMBL13939142

SCHEMBL13939142

Nc1ccc(CCNP)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GFER P55789 1/20 0.59
▸ MAOB P27338 5/20 0.50
▸ MAOA P21397 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.46
▸ CYP3A4 P08684 2/20 0.46
▸ TSHR P16473 2/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA6 P23280 1/20 0.44
▸ CA5A P35218 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ CA5B Q9Y2D0 1/20 0.44
▸ LOXL2 Q9Y4K0 1/20 0.44
▸ CYP19A1 P11511 3/20 0.43
▸ RECQL P46063 1/20 0.42
▸ PRMT1 Q99873 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL681443 0.76 TAAR1 (0.61) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL20831067 0.76 TMEM97 (0.61) ALDH1A1TDP1CA2KMT2ALMNA
SCHEMBL7521617 0.76 GFER (0.59) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL22330599 0.76 GFER (0.59) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL187043 0.76 GFER (1.00) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL3482833 0.76 GFER (1.00) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL8164156 0.76 GFER (1.00) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL23266841 0.76 GFER (0.52) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL12712080 0.74 GFER (0.56) GFERMAOBMAOAALDH1A1CYP3A4
SCHEMBL16682342 0.74 GAA (0.59) GFERMAOBMAOAALDH1A1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1666480-B1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. RAQUALIA PHARMA INC (JP) 2014-10-01 — — EP disclosed
US-7479564-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents RAQUALIA PHARMA INC. (JP) 2009-01-20 — — US disclosed
US-7479564-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents RAQUALIA PHARMA INC. (JP) 2009-01-20 — — US disclosed
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PFIZER INC. 2007-07-05 — — US disclosed
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PFIZER INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PTGS1, PTGS2, PTGES GFER 3882/4885MAOB 1399/4885MAOA 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback